EHAB Q2 2025: Hospice Margin Expands 520bps as Home Health Braces for 6.4% CMS Cut
EHAB’s Q2 showcased robust hospice margin expansion and disciplined cost control, but regulatory headwinds loom large for 2026. Management’s operational levers and payer strategy are being stress-tested by CMS’s proposed home health cuts, even as hospice growth and payer renegotiations drive near-term upside. Investors should closely track pilot outcomes and volume recovery as the reimbursement landscape shifts.
Summary
- Hospice Margin Acceleration: Double-digit hospice growth and 520bps margin expansion signal sustained segment strength.
- Operational Levers Intensify: Advanced visit management and branch closures are being piloted to offset regulatory risk.
- Payer Mix and Rate Reset: Recent contract renegotiations improved rates, but volume stability remains a key watchpoint.
Performance Analysis
EHAB delivered sequential and year-over-year revenue growth in Q2, marking the first consolidated YoY revenue increase post-spend and the third straight quarter of sequential growth. Hospice continued to outperform, with revenue up nearly 20% YoY and admissions and census both posting double-digit gains. Hospice adjusted EBITDA grew 54% YoY, and segment margin surged 520 basis points, reflecting strong operating leverage as volumes scale and cost per day remained tightly controlled. Home health revenue grew sequentially but remained below prior-year levels, reflecting ongoing pressure from payer mix shifts and lower unit revenues. Notably, Medicare volumes stabilized, with the rate of decline sharply reduced versus last year, demonstrating progress on payer balance initiatives.
Cost discipline was evident, with G&A as a percentage of revenue down nearly a full point YoY, driven by targeted branch closures and operational efficiencies. Free cash flow conversion remained robust at 52% YTD, supporting ongoing debt reduction and liquidity improvement. However, management’s tone reflected urgency around the CMS’s proposed 6.4% home health rate cut for 2026, with multiple mitigation levers in play but no certainty of full offset.
- Hospice Outperformance: All regions delivered double-digit revenue growth, and census rose 12.3% YoY, leveraging prior cost investments.
- Home Health Stabilization: Medicare patient volume declines slowed to 3.4% YoY from 14% last year, aided by payer mix initiatives.
- Cost Structure Action: Eleven branches closed or consolidated, with further reductions and advanced visit-per-episode pilots underway.
Overall, the quarter balanced strong hospice execution with a clear-eyed view of reimbursement risk and operational adaptation in home health.
Executive Commentary
"Our size and scale coupled with our recent investments in technology and operational improvements put us in a position to address the challenges of this moment... Evaluating these and other potential levers is necessary to ensure we can maintain competitive wage rates to recruit and retain our skilled workforce within a highly competitive labor market."
Barb Jacobsmeyer, President and Chief Executive Officer
"The cumulative permanent and temporary rate cuts since PDGM implementation now total over 20% with the recent proposed rule, all at a time where cost of care for home health providers has rapidly increased. Our scalable operating model, proprietary clinical pathways, disciplined cost structure, and improved leverage give us distinct advantages relative to others in this environment."
Ryan Solomon, Chief Financial Officer
Strategic Positioning
1. Hospice as a Growth and Margin Engine
Hospice, end-of-life care services, continues to deliver robust volume and margin expansion, with all regions posting double-digit growth and segment margin reaching 23.3%. The segment now leverages prior cost investments, and de novo expansion remains on track, with ten new locations targeted for 2025.
2. Home Health Resilience Amid CMS Pressure
Home health, in-home skilled nursing and therapy, faces the brunt of regulatory risk, but management’s payer contract strategy and visit-per-episode optimization are slowing Medicare volume decline and stabilizing census. Advanced visit management pilots, which limit clinician overrides, are being deployed to further offset reimbursement pressure.
3. Payer Innovation and Rate Reset
Payer innovation contracts, value-based arrangements with insurers, are now a focal point. A recent renegotiation with a national payer yielded a low double-digit rate increase, moving the contract into the higher-value innovation tier. Management expects more contracts to come up for renewal in 2026, with negotiations starting well in advance.
4. Cost Structure and Deleveraging
Eleven branch closures and ongoing G&A reductions have reduced overhead and supported margin improvement. Free cash flow is being directed toward debt reduction, with five straight quarters of prepayments totaling $50 million, lowering annual interest expense by $10 million and reducing leverage to 4.3x.
5. Leadership Transition Planning
CEO Barb Jacobsmeyer announced her intent to step down by July 2026, with a transition plan in place. The timing is positioned as optimal for a new leader to build on the operational foundation and adapt to the next phase of industry change.
Key Considerations
Q2’s operational and financial results highlight EHAB’s ability to execute through industry headwinds, but the 2026 CMS proposal is a structural challenge that will test the scalability and adaptability of the business model.
Key Considerations:
- Regulatory Volatility: The proposed 6.4% home health rate cut for 2026, on top of prior cumulative cuts, poses a material earnings risk that may force further operational changes or branch rationalization.
- Payer Mix Management: Stabilizing Medicare fee-for-service volumes and growing payer innovation contracts are critical for margin and volume resilience, especially as MA penetration rises in core markets.
- Operational Levers in Focus: Advanced visit-per-episode pilots and tighter override controls could unlock $5-8 million per 0.5 VPE reduction, but quality and capacity impacts must be closely monitored.
- Volume Recovery Post-Disruption: The national payer contract disruption temporarily reduced census by 600, but early signs point to rapid recovery, with admissions now above average weekly levels.
Risks
The principal risk remains regulatory: If the CMS finalizes the proposed 6.4% cut, EHAB’s home health economics could be structurally impaired, especially if operational levers fall short of full offset. Payer renegotiations, labor market tightness, and further branch closures could impact both growth and quality, while leadership transition adds an additional layer of uncertainty in strategic execution.
Forward Outlook
For Q3 2025, EHAB expects:
- Continued hospice census and revenue growth, with de novo locations ramping.
- Pilot results from advanced visit-per-episode management to inform broader rollout.
For full-year 2025, management raised guidance:
- Revenue range: $1.060 billion to $1.073 billion
- Adjusted EBITDA: $104 million to $108 million
- Adjusted free cash flow: $47 million to $57 million
Management emphasized that guidance assumes no material change to the CMS proposal and that further operational actions will be evaluated as the regulatory picture clarifies.
- Branch rationalization and G&A control will continue.
- Payer contract renewals and volume recovery are key watchpoints.
Takeaways
EHAB’s Q2 confirms the company’s ability to drive margin and growth in hospice, while home health remains exposed to external regulatory risk and internal execution on operational levers.
- Hospice Drives Margin: Double-digit growth and margin expansion provide a buffer as home health faces structural headwinds.
- Operational Flex Remains Critical: Management’s willingness to pilot, close branches, and renegotiate contracts will determine resilience in 2026 and beyond.
- Regulatory Uncertainty Dominates Outlook: Investors should monitor CMS developments and management’s ability to deliver on cost and volume initiatives.
Conclusion
EHAB’s Q2 performance highlights the importance of scale, payer strategy, and operational agility in a challenged reimbursement environment. While hospice momentum is robust, home health faces a pivotal test in the coming year as regulatory and market forces converge.
Industry Read-Through
EHAB’s results reinforce the widening gap between scaled and subscale providers in home-based care. The ability to absorb regulatory shocks, renegotiate payer contracts, and execute rapid cost actions will likely define industry winners as CMS reimbursement tightens. The hospice segment’s sustained growth and margin expansion may prompt peers to double down on end-of-life services, while ongoing branch rationalization signals more consolidation ahead. For the broader post-acute sector, CMS policy risk and MA penetration remain the defining forces shaping provider strategy and investor returns.